Capricor Therapeutics, Inc. (CAPR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$9.40+1.29%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CAPR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 14.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CAPR — capital allocation
Dated 2026-07-14
by reference. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CAPRICOR THERAPEUTICS, INC. Date: July 14, 2026 By: /s/ Linda Marbán, Ph.D. Linda Marbán, Ph.D. Chief Executive Officer 3
Why it matters: The earnings report will provide updates on revenue and expenses. Investors will look for signs of improvement.
Watch forThe earnings report shows more money made or fewer losses than before.
Also watch forThe earnings report shows more losses or less money made.
Why it matters: This hire may improve Capricor's plan for launching Deramiocel.
Supportive ifThe new CCO is announced. They have experience in DMD sales.
Worry ifThe appointment is delayed. The candidate may not have the right experience.
Why it matters: This date is when the FDA will decide on the approval of Deramiocel. Approval could lead to a commercial launch.
Supportive ifThe FDA approves the BLA for Deramiocel by the PDUFA date.
Worry ifThe FDA delays the decision or issues a complete response letter.
Why it matters: The FDA inspection results can change when Deramiocel gets approved.
Worry ifCapricor gets good feedback from the FDA about the BIMO inspection.
Less concerning ifThe FDA issues further concerns or delays related to the BIMO inspection.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$339 on $10,000 · ±3.4% | How much price usually moves either way. |
| Bad day | $856 loss on $10,000 · 8.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,911 loss on $10,000 · 89.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Having enough cash is key for Capricor's operations and growth.
Worry ifAn announcement that cash is sufficient through Q4 2027.
Less concerning ifNews about cash shortages or funding issues.
Why it matters: Capricor needs enough cash to support its operations and growth.
Watch forCapricor announces a successful capital raise or cost cuts. This helps cash flow.
Also watch forCapricor uses more cash than expected. This raises worries about having enough money.
Why it matters: If healthcare sector growth speeds up, it could benefit Capricor. This would signal a better environment for biotech firms.
Supportive ifHealthcare sector revenue growth returns to near 10% or higher.
Worry ifHealthcare sector revenue growth keeps slowing down below current levels.
Why it matters: FDA approval is crucial for Capricor's growth and future revenue. It could boost investor confidence.
Supportive ifFDA approves Deramiocel. It can now enter the market.
Worry ifFDA denies Deramiocel's approval. This delays its entry into the market.
Why it matters: The lawsuit's outcome could impact Capricor's deals and financial health.
Watch forCapricor reaches a good settlement in the lawsuit.
Also watch forCapricor faces problems or bad results in the lawsuit.
Why it matters: The FDA inspection results can change when Deramiocel gets approved.
Worry ifThe FDA inspection finds no big problems. This helps the approval process.
Less concerning ifThe FDA inspection finds serious problems. This slows down the approval for Deramiocel.